The overall growth rate of the chemical preparation industry has improved, and focus on this type of enterprise

 Chemical preparations are widely used daily pharmaceutical products by Chinese residents
.
In recent years, with China's significant increase in public medical investment, as well as the steady economic growth, the improvement of people's living standards, and the enhancement of health awareness, the domestic chemical pharmaceutical preparation market has maintained rapid growth
.
Statistics show that from 2013 to 2020, the sales of chemical drugs in urban and county-level public hospitals in China have increased from 582.
1 billion yuan to 836.
6 billion yuan, a compound annual growth rate of more than 5%
.
In addition, statistics show that in the first three quarters of 2021, the total revenue of 90 chemical drug preparation companies increased by 9.
81% year-on-year, the total net profit attributable to the parent company increased by 9.
54% year-on-year, and the total non-net profit increased by 13.
31% year-on-year
.
In the third quarter of 2021, the total revenue of these 90 companies increased by 3.
5% year-on-year, the total net profit attributable to the parent company increased by 11.
8% year-on-year, and the total non-net profit increased by 16.
2% year-on-year.
The overall growth rate has improved
.
Some analysts pointed out that at present, China's chemical pharmaceutical preparation industry has entered a stage of rapid differentiation, structural upgrading, and elimination of backward production capacity.
In the future, companies with independent pharmaceutical innovation capabilities and intellectual property protection will be in a dominant position in the chemical preparations competitive market.

.
Others also said that innovation and competition are the keywords for the development of the chemical preparation industry.
Therefore, in the development process, focus on companies with innovative capabilities
.
The person said that he recommends Hengrui Pharmaceuticals, Betta Pharmaceuticals, etc.
; recommended attention: Zejing Pharmaceuticals
.
Then the author will take you to see these three pharmaceutical companies
.
Among them, Hengrui Pharmaceuticals is currently a giant company in the domestic pharmaceutical industry.
With "technological innovation" and "internationalization" as its development direction, it has generated 15.
163 billion yuan in net cash flow through operating activities in the past five years, creating 21.
528 billion yuan.
Yuan profit
.
The company has launched innovative drugs in 1-2 years.
Currently, there are more than 240 clinical projects, 23 international multi-center clinics, 5 production approvals for innovative drug preparations, 9 production approvals for generic drugs, and 41 clinical drug approvals.

.
In the future, the growth potential of Hengrui Medicine lies in its reserves of "anti-tumor drugs, surgical anesthetics, special infusions, contrast agents, and innovative drugs for cardiovascular drugs"
.
According to the data, it has 10 projects under construction, with an investment plan of 5.
453 billion yuan, 33% of the progress of the "Bio-industrial Park" related to new capacity, 99.
35% of the "New Pharmaceutical Industrial Park", and "Chengdu Xinyue Raw Material Plant Phase II" 80 %, "Guangdong Hengrui Biological Island" 15%, "Guangdong Hengrui Knowledge City" 50%, "Suzhou Shengdiya Dongsha Lake Phase II" 40%, the completed construction of "Chengdu Shengdi Preparation Plant Phase II" and " "Suzhou Shengdi Dongsha Lake Phase I" started production
.
The 2021 semi-annual report released by Hengrui Medicine shows that the company's R&D expenditure in the first half of this year was 2.
581 billion yuan, a year-on-year increase of 38.
48%
.
R&D investment accounted for 19.
41% of sales revenue
.
As the “research and development brother” in the pharmaceutical industry, Hengrui Pharmaceuticals, on the way of transforming generic drugs into innovative drugs, focuses on research and development on the one hand, and on the other hand, it also leverages innovative pharmaceutical companies to seek breakthroughs
.
As for Betta Pharmaceuticals, some analysts said that although it is a small company on the Growth Enterprise Market that has been listed for five years, it maintains high R&D investment all the year round and the R&D expense ratio exceeds Hengrui Pharmaceuticals, which is a force that cannot be ignored
.
According to the data, from 2018 to 2020, Betta Pharmaceuticals invested 590 million yuan, 670 million yuan, and 740 million yuan in R&D respectively, and the proportions of R&D investment in operating revenue during the same period were 48.
2%, 43.
41%, and 39.
69%
.
In the first three quarters of 2021, the company's R&D expenses increased by 37.
02% year-on-year to 366 million yuan
.
According to reports, Betta Pharmaceuticals spends 40% of its revenue on innovation and continues to increase R&D investment
.
At present, Betta Pharmaceuticals has more than 30 innovative drugs under development, 18 of which have entered the clinical research phase, and 4 of them are in the final phase of clinical research before the launch of the new drug
.
According to the industry, if Betta Pharmaceuticals can successfully go to Hong Kong for an IPO, this will provide a stable source of funds for new drug research and development.
In the next 5 years, it may be a period of intensive listing of new drugs for Betta Pharmaceuticals.
By then, it will be in the field of anti-cancer drugs.
Form a rich product matrix
.
Next, let’s take a look at Zejing Pharmaceuticals.
It is understood that Zejing Pharmaceuticals is an innovation-driven chemical and biological new drug research and development and production enterprise focusing on multiple therapeutic fields such as tumors, bleeding and blood diseases, liver and gallbladder diseases, and immune inflammatory diseases.

.
The company's product pipeline covers both large and small molecule new drugs.
The commercialized product is a new class 1 drug Donafinil tosylate tablets, which is used in the first-line treatment of advanced hepatocellular carcinoma.
The company is actively carrying out market promotion and sales
.
In addition, the company has 37 research projects of 13 major drugs under research
.
The 6 indications of 4 of the drugs under study are in the NDA or phase III clinical trial stage, including Donafenib tablets for the treatment of locally advanced/metastatic radioiodine refractory differentiated thyroid cancer indications, and Jieketinib tablets.
indications risk myelofibrosis, Jack nylon sheet for severe alopecia areata and other indications
.
3 research drugs are in phase I or II clinical trials (okatinib capsules, jacktinib cream and magnesium obeticholate tablets), 6 research drugs are in preclinical development or IND stage (ZG19018, ZG170607 , ZG1905, ZG005, ZG006, ZGGS001)
.
It is understood that Zejing Pharmaceutical's market strategy is to face the world, focus on China, develop and produce innovative drugs with independent intellectual property rights, safe, effective, and affordable for patients to meet the huge domestic and foreign pharmaceutical market needs
.
At present, the company has a high-level new drug research and development technology platform, while focusing on international and domestic technology and project cooperation and expansion, relying on the research and development advantages in tumors, blood diseases and immune inflammatory diseases, etc.
, to provide patients with better treatment options
.
The company plans to increase investment in research and development, further promote the development of new drugs such as Jacketinib hydrochloride tablets, ZG19018 tablets, ZG005 powder injection, ZG170607 injection, ZG006 powder injection and GS11 powder injection, and global simultaneous development, expand the company's product pipeline, and further strengthen The differentiated competitive advantage of the company's product pipeline
.
However, it is worth noting that Zejing Pharmaceutical is still at a loss
.